Anthony Rothschild, MD, the Irving S. and Betty Brudnick Chair in Psychiatry and professor of psychiatry, will lead the study at UMass Chan. Dr. Rothschild is interested in studying new treatments for depression, particularly treatment-resistant depression, a term used to describe patients with depression who have symptoms that don’t respond to multiple antidepressant medications.
“Psilocybin could provide an option for people who have not derived benefit from the current treatments that are on the market,” he said.
Psilocybin is a tryptamine alkaloid found in several species of mushrooms, often referred to as “magic mushrooms.” Psilocybin therapy combines the pharmacological effects of psilocybin with psychological support.
